Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Stock Information for Rocket Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI(TM) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.